Evolution of immunosuppression at the University of Minnesota

A. J. Matas; D. E R Sutherland; J. S. Najarian

doi:10.1016/j.transproceed.2004.01.062

Evolution of immunosuppression at the University of Minnesota

A. J. Matas, D. E R Sutherland, J. S. Najarian

Surgery

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Immunosuppressive protocols at the University of Minnesota have evolved from identical immunosuppression for all recipients (prednisone, azathioprine, and antilymphocyte globulin) to differing protocols for living (triple therapy) and cadaver (sequential therapy) donor recipients, and then to our current protocol in which all recipients receive induction therapy with rapid discontinuation of prednisone. At the same time, progress has been made in the prevention and treatment of cytomegalovirus infection along with numerous parallel improvements in patient care, including in anesthesia, dialysis, and intensive care unit care. The net result has been an incremental improvement in recipient and graft survival.

Original language	English (US)
Pages (from-to)	S64-S70
Journal	Transplantation proceedings
Volume	36
Issue number	2 SUPPL.
DOIs	https://doi.org/10.1016/j.transproceed.2004.01.062
State	Published - Mar 2004

Bibliographical note

Funding Information:
Supported by NIH Grant #13083.

Access

10.1016/j.transproceed.2004.01.062

OpenUrl availability

Full text

Cite this

@article{129631f965fd4a1182583aebb28e48a3,

title = "Evolution of immunosuppression at the University of Minnesota",

abstract = "Immunosuppressive protocols at the University of Minnesota have evolved from identical immunosuppression for all recipients (prednisone, azathioprine, and antilymphocyte globulin) to differing protocols for living (triple therapy) and cadaver (sequential therapy) donor recipients, and then to our current protocol in which all recipients receive induction therapy with rapid discontinuation of prednisone. At the same time, progress has been made in the prevention and treatment of cytomegalovirus infection along with numerous parallel improvements in patient care, including in anesthesia, dialysis, and intensive care unit care. The net result has been an incremental improvement in recipient and graft survival.",

author = "Matas, {A. J.} and Sutherland, {D. E R} and Najarian, {J. S.}",

note = "Funding Information: Supported by NIH Grant #13083. ",

year = "2004",

month = mar,

doi = "10.1016/j.transproceed.2004.01.062",

language = "English (US)",

volume = "36",

pages = "S64--S70",

journal = "Transplantation proceedings",

issn = "0041-1345",

publisher = "Elsevier USA",

number = "2 SUPPL.",

}

TY - JOUR

T1 - Evolution of immunosuppression at the University of Minnesota

AU - Matas, A. J.

AU - Sutherland, D. E R

AU - Najarian, J. S.

N1 - Funding Information: Supported by NIH Grant #13083.

PY - 2004/3

Y1 - 2004/3

N2 - Immunosuppressive protocols at the University of Minnesota have evolved from identical immunosuppression for all recipients (prednisone, azathioprine, and antilymphocyte globulin) to differing protocols for living (triple therapy) and cadaver (sequential therapy) donor recipients, and then to our current protocol in which all recipients receive induction therapy with rapid discontinuation of prednisone. At the same time, progress has been made in the prevention and treatment of cytomegalovirus infection along with numerous parallel improvements in patient care, including in anesthesia, dialysis, and intensive care unit care. The net result has been an incremental improvement in recipient and graft survival.

AB - Immunosuppressive protocols at the University of Minnesota have evolved from identical immunosuppression for all recipients (prednisone, azathioprine, and antilymphocyte globulin) to differing protocols for living (triple therapy) and cadaver (sequential therapy) donor recipients, and then to our current protocol in which all recipients receive induction therapy with rapid discontinuation of prednisone. At the same time, progress has been made in the prevention and treatment of cytomegalovirus infection along with numerous parallel improvements in patient care, including in anesthesia, dialysis, and intensive care unit care. The net result has been an incremental improvement in recipient and graft survival.

UR - http://www.scopus.com/inward/record.url?scp=1642287622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642287622&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2004.01.062

DO - 10.1016/j.transproceed.2004.01.062

M3 - Article

C2 - 15041309

AN - SCOPUS:1642287622

SN - 0041-1345

VL - 36

SP - S64-S70

JO - Transplantation proceedings

JF - Transplantation proceedings

IS - 2 SUPPL.

ER -

Evolution of immunosuppression at the University of Minnesota

Abstract

Bibliographical note

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this